|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023981,
umls-concept:C0024301,
umls-concept:C0032520,
umls-concept:C0034656,
umls-concept:C0087111,
umls-concept:C0205263,
umls-concept:C0205390,
umls-concept:C0242792,
umls-concept:C0332325,
umls-concept:C0376515,
umls-concept:C0444930,
umls-concept:C0449438,
umls-concept:C0681890,
umls-concept:C1274040,
umls-concept:C1516985,
umls-concept:C2603343
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2010-4-30
|
|
pubmed:abstractText |
The prognostic value of residual BCL2/immunoglobulin heavy chain (BCL2/IgH) -positive cells in peripheral blood (PB) or bone marrow (BM) after induction treatment in follicular lymphoma (FL) is still controversial. In a prospective randomized phase III intergroup trial of 465 patients with relapsed/resistant follicular lymphoma (FL), we showed that addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone induction results in increased overall and complete response rates, and that rituximab maintenance strongly improves median progression-free survival (PFS) as well as overall survival. Here, we studied whether BCL2/IgH major break point levels in PB/BM correlated with response rates/quality for the induction phase and PFS for the maintenance phase.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:GiurgeaLiviaL,
pubmed-author:HagenbeekAntonA,
pubmed-author:HolteHaraldH,
pubmed-author:JansenJoop HJH,
pubmed-author:KimbyEvaE,
pubmed-author:KlasaRichardR,
pubmed-author:MarcusRobert ERE,
pubmed-author:TönnissenEvelynE,
pubmed-author:Van GlabbekeMartineM,
pubmed-author:VranovskyAndrejA,
pubmed-author:WolfMaxM,
pubmed-author:van OersMarinus H JMH,
pubmed-author:van der ReijdenBert ABA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2246-52
|
|
pubmed:dateRevised |
2011-5-25
|
|
pubmed:meshHeading |
pubmed-meshheading:20368567-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20368567-Australia,
pubmed-meshheading:20368567-Canada,
pubmed-meshheading:20368567-Cyclophosphamide,
pubmed-meshheading:20368567-Disease-Free Survival,
pubmed-meshheading:20368567-Doxorubicin,
pubmed-meshheading:20368567-Drug Resistance, Neoplasm,
pubmed-meshheading:20368567-Europe,
pubmed-meshheading:20368567-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20368567-Genes, Immunoglobulin Heavy Chain,
pubmed-meshheading:20368567-Genetic Testing,
pubmed-meshheading:20368567-Humans,
pubmed-meshheading:20368567-Kaplan-Meier Estimate,
pubmed-meshheading:20368567-Logistic Models,
pubmed-meshheading:20368567-Lymphoma, Follicular,
pubmed-meshheading:20368567-New Zealand,
pubmed-meshheading:20368567-Polymerase Chain Reaction,
pubmed-meshheading:20368567-Predictive Value of Tests,
pubmed-meshheading:20368567-Prednisone,
pubmed-meshheading:20368567-Proportional Hazards Models,
pubmed-meshheading:20368567-Prospective Studies,
pubmed-meshheading:20368567-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:20368567-Recurrence,
pubmed-meshheading:20368567-Risk Assessment,
pubmed-meshheading:20368567-Risk Factors,
pubmed-meshheading:20368567-South Africa,
pubmed-meshheading:20368567-Time Factors,
pubmed-meshheading:20368567-Treatment Failure,
pubmed-meshheading:20368567-Vincristine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
|
|
pubmed:affiliation |
Department of Hematology F4-224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. M.H.vanOers@AMC.UVA.NL
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
